Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Clin Nucl Med. 2023 May 1;48(5):e217-e218. doi: 10.1097/RLU.0000000000004612. Epub 2023 Mar 5.

Abstract

Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [ 177 Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [ 177 Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dipeptides / therapeutic use
  • Glioblastoma* / diagnostic imaging
  • Glioblastoma* / drug therapy
  • Glioblastoma* / radiotherapy
  • Heterocyclic Compounds, 1-Ring / therapeutic use
  • Humans
  • Lutetium / therapeutic use
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Radiopharmaceuticals / therapeutic use
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Prostate-Specific Antigen
  • Lutetium-177
  • Lutetium
  • Heterocyclic Compounds, 1-Ring
  • Dipeptides